Cutaneous events during anti-TNF alpha therapy: A prospective observational study of 41 cases;Événements cutanéomuqueux au cours des traitements par anti-TNF alpha : étude observationnelle prospective de 41 cas

Annales de Dermatologie et de Venereologie

Volumn 137, Issue 1, 2010, Pages 12-20

  Bonnet, N ^a   Guis, S ^b   Koeppel, M C ^a   Roudier, J ^b   Grimaud, J C ^a   Jean Pastor, M J ^c   Berbis, P ^a  

^a HÔPITAL NORD   (France)

^b HÔPITAL DE LA CONCEPTION   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

Author keywords

Anti TNF alpha therapy; Cutaneous events; Drug reaction

Indexed keywords

ADALIMUMAB; CD20 ANTIBODY; CORTICOSTEROID; ETANERCEPT; HISTAMINE H1 RECEPTOR ANTAGONIST; INFLIXIMAB; METHOTREXATE; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ACANTHOMA; ADULT; AGED; ALOPECIA; ANKYLOSING SPONDYLITIS; ARTICLE; BASAL CELL CARCINOMA; CHICKENPOX; CLINICAL ARTICLE; CROHN DISEASE; DRUG ERUPTION; DRUG INDICATION; DRUG SAFETY; DRUG WITHDRAWAL; ECZEMA; FEMALE; FOLLICULITIS; FOLLOW UP; HUMAN; LICHEN PLANUS; LYMPHADENOPATHY; MALE; MELANOMA; OBSERVATIONAL STUDY; PARAPSORIASIS; POLYARTHRITIS; PROSPECTIVE STUDY; PRURITUS; PSORIASIS; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; RECTUM HEMORRHAGE; RHEUMATOID ARTHRITIS; SEBORRHEIC DERMATITIS; SKIN LUPUS ERYTHEMATOSUS; SKIN MANIFESTATION; STAPHYLOCOCCUS INFECTION; TICK BORNE DISEASE; VITILIGO; ADOLESCENT; ANAPHYLAXIS; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; ERYTHEMATOSQUAMOUS SKIN DISEASE; MIDDLE AGED; SKIN INFECTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANAPHYLAXIS; ANTIBODIES, MONOCLONAL; DRUG ERUPTIONS; ECZEMA; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, CUTANEOUS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECEPTORS, TUMOR NECROSIS FACTOR; SKIN DISEASES, INFECTIOUS; SKIN DISEASES, PAPULOSQUAMOUS; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 74149087430     PISSN: 01519638     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.annder.2009.12.003     Document Type: Article

References (21)

1. Ko J.M., Gottlieb A.B., and Kerbleski J.F. Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases. J Dermatolog Treat 20 (2009) 100-108
2. Harrison M.J., Dixon W.G., Watson K.D., King Y., Groves Y., Hyrich K.L., et al. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor α therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 68 (2009) 209-215
3. Bégaud B., Evreux J.C., Jouglard J., and Lagier G. Imputabilité des effets inattendus ou toxiques des médicaments. Therapie 40 (1985) 111-118
4. Flendrie M., Vissers W.H., Creemers M.C., De Jong E.M., Van de Kerkhof P.C., Van Riel P.L., et al. Dermatological conditions during TNF-α-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther 7 (2005) R666-R676
5. Devos S.A., Van Den Bossche N., De Vos M., and Naeyaert J.M. Adverse skin reactions to anti TNF-alpha monoclonal antibody therapy. Dermatology 206 (2003) 388-390
6. Battistella M., Rivet J., Bachelez H., and Lioté F. Lichen planus associated with etanercept. Br J Dermatol 158 (2008) 188-189
7. Deng A., Harvey V., Sina B., Strobel D., Badros A., Junkins-Hopkins J., et al. Interstitial granulomatous dermatitis associated with the use of tumor necrosis factor α inhibitors. Arch Dermatol 142 (2006) 198-202
8. Lebas D., Staumont-Sallé D., Solau-Gervais E., Flipo R.M., and Delaporte E. Manifestations cutanées observées au cours d'un traitement par anti-TNFα : 11 observations. Ann Dermatol Venereol 134 (2007) 337-342
9. De Gannes G.C., Ghoreishi M., Pope J., Russell A., Bell D., Adams S., et al. Psoriasis and pustular dermatitis triggered by TNF-( inhibitors in patients with rheumatologic conditions. Arch Dermatol 143 (2007) 223-231
10. Kary S., Worm M., Audring H., Huscher D., Renelt M., Sorensen H., et al. New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor ( antagonists. Ann Rheum Dis 65 (2006) 405-407
11. Passarini B., Infusino S.D., Barbieri E., Varotti E., Gionchetti P., Rizzello F., et al. Cutaneous manifestations in inflammatory bowel diseases: eight cases of psoriasis induced by anti-tumor-necrosis-factor antibody therapy. Dermatology 215 (2007) 295-300
12. Fabre S., Gibert C., Lechiche C., Jorgensen C., and Sany J. Primary cutaneous Nocardia otitidiscaviarum infection in a patient with rheumatoid arthritis treated with infliximab. J Rheumatol 32 (2005) 2432-2433
13. Vestergaard C., Deleuran M., and Kragballe K. Two cases of atopic dermatitis-like conditions induced in psoriasis patients treated with infliximab. J Eur Acad Dermatol Venereol 21 (2007) 1272-1274
14. Ramos-Casals M., Brito-Zeron P., Munoz S., Soria N., Galiana D., Bertolaccini L., et al. Autoimmune diseases induced by TNF-targeted therapies, analysis of 233 cases. Medicine 86 (2007) 242-251
15. Tyring S., Gottlieb A., Papp K., Gordon K., Leonardi C., Wang A., et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 367 (2007) 29-35
16. Smith K.J., and Skelton H.G. Rapid onset of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis after starting tumor necrosis factor α receptor IgG1-Fc fusion complex therapy. J Am Acad Dermatol 45 (2001) 953-956
17. Esser A.C., Abril A., Fayne S., and Doyle J.A. Acute development of multiple keratoacanthomas and squamous cell carcinomas after treatment with infliximab. J Am Acad Dermatol 50 Suppl. (2004) S75-S77
18. Lebwohl M., Blum R., Berkowitz E., Kim D., Zitnik R., Osteen C., et al. No evidence for increased risk of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis receiving etanercept for up to 5 years. Arch Dermatol 141 (2005) 861-864
19. Dauendorffer J.N., Rivet J., Allard A., and Bachelez H. Sezary syndrome in a patient receiving infliximab for ankylosing spondylilis. Br J Dermatol 156 (2007) 742-743
20. Sanli H., Ataman S., Akay B.N., Yilmaz A., Yildizlar D., and Gurgey E. Mycosis fungoides in a patient with ankylosing spondylitis during infliximab therapy. J Drugs Dermatol 6 (2007) 834-836
21. Fulchiero Jr. G.J., Salvaggio H., Drabick J., Staveley-O'Carroll K., Billingsley E.M., Marks J.G., et al. Eruptive latent metastatic melanomas after initiation of antitumor necrosis factor therapies. J Am Acad Dermatol 56 (2007) S65-S67